RIGEL PHARMACEUTICALS INC Cash Flow Statement
RIGL / Health Care|11 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
RIGEL PHARMACEUTICALS INC generated $76M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $367.0M | $17.5M | -$25.1M | -$58.6M | -$17.9M | -$29.7M | -$66.9M | -$69.2M | -$78.0M | -$69.2M | -$51.5M |
| Depreciation & Amortization | $2.4M | $2.2M | $1.2M | $998.0K | $1.2M | $706.0K | $683.0K | $941.0K | $465.0K | $941.0K | $1.4M |
| Operating Cash Flow | $75.7M | $31.5M | -$5.7M | -$73.8M | $5.9M | -$52.2M | -$41.5M | -$75.9M | -$77.6M | -$75.9M | -$23.4M |
| Capital Expenditures | - | - | - | $450.0K | $627.0K | $1.3M | $1.5M | $804.0K | $164.0K | $804.0K | $546.0K |
| Free Cash Flow | - | - | - | -$74.2M | $5.3M | -$53.4M | -$43.0M | -$76.7M | -$77.7M | -$76.7M | -$24.0M |
| FCF Margin | - | - | - | -61.7% | 3.5% | -49.2% | -72.5% | -376.3% | - | - | - |